edited by
Sherry X. Yang
Janet E. Dancey

Handbook of THERAPEUTIC BIOMARKERS IN CANCER

edited by
Sherry X. Yang
Janet E. Dancey

Handbook of

THERAPEUTIC BIOMARKERS IN CANCER

藏书章

PAN STANFORD PUBLISHING

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com
Web: www.panstanford.com

British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library.

Handbook of Therapeutic Biomarkers in Cancer

Copyright © 2013 by Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4364-65-2 (Hardcover)
ISBN 978-981-4364-66-9 (eBook)

Printed in the USA

Handbook of

THERAPEUTIC BIOMARKERS IN CANCER

Preface

The advent of the era of the molecularly targeted therapy in oncology in addition to conventional multimodality management signifies more hope for cancer patients. The discovery, validation, and clinical applications of biomarkers of prognosis and prediction are advancing the promise of personalized medicine. The clinically validated therapeutic (predictive) biomarkers for targeted and chemotherapy agents approved for use or having potential to be approved by the regulatory agencies such as the United States Food and Drug Administration facilitate the evolution of empiric therapy to individually tailored treatment. In essence, therapeutic biomarkers and appropriately validated clinical assays facilitate treatment decision-making. We have clearly entered the epoch that patients can receive the right drugs with the right doses at the right time with greater assurance of maximal benefits and reduced risks.

In editing and organizing the *Handbook of Therapeutic Biomarkers in Cancer*, we have made every attempt to cover the growing numbers of promising predictive biomarkers and associated assays in the fields of oncology and cancer research. We hope that many readers—oncologists, health professionals, patients, scientists involved in basic, translational, and clinical research, educators, and students both medical and undergraduate—will find each chapter of this book a valuable source of information and guidance.

It has been a great privilege to be involved in editing this book. We express our sincere thanks to all authors who have contributed their expertise, experience, and hard work to this book for publication. In addition, we welcome comments for planning future editions.

Sherry X. Yang

Janet E. Dancey

此为试读，需要完整PDF请访问：www.ertongbook.com

Contents

Preface xix

1. Overview: Therapeutic Biomarkers in Cancer **1**

Sherry X. Yang and Janet E. Dancey

1.1 Introduction 2
1.2 Classification of Therapeutic Biomarkers 3
1.3 Chemotherapy Agents and Therapeutic Biomarkers 3
1.4 Targeted Cancer Therapeutics and Biomarkers 7
1.4.1 Targeted Cancer Therapeutics 7
1.4.2 Biomarker Validation 8
1.4.3 Therapeutic Biomarkers of Targeted Therapy 8
1.4.3.1 Direct drug targets as therapeutic biomarkers 8
1.4.3.2 Indirect drug targets as therapeutic biomarkers 12
1.4.3.3 Anti-angiogenesis therapy and biomarkers 13
1.5 Targeted Therapeutics in Combination with Chemotherapy and Therapeutic Biomarkers 17
1.6 Multi-Gene Expression or Signatures for Cancer Prognosis and Treatment 19
1.7 Diagnostic Techniques for Therapeutic Biomarkers 21
1.8 Conclusions and Perspectives 21

2. Statistical Considerations in the Development and Evaluation of Therapeutic Biomarkers in Cancer **31**

Lisa M. McShane, Edward L. Korn, and Boris Freidlin

2.1 Introduction 31
2.2 Analytical Performance of a Biomarker-Based Test 32
2.3 Prognostic versus Predictive Biomarkers 37

2.4 Biomarker Evaluations in Phase I Trials 38
2.5 Biomarker Evaluations in Phase II Trials 40
2.5.1 Designs Involving Single Biomarkers 42
2.5.2 Designs Involving Multiple Biomarkers 43
2.6 Biomarker Evaluations in Phase III Trials 44
2.6.1 Biomarker-Stratified Designs 44
2.6.2 Enrichment Designs 47
2.6.3 Biomarker-Strategy Designs 49
2.6.4 Designs in Which the Biomarker Has Not Been Completely Specified 50
2.7 Summary 52

3. Role of Biomarkers in Clinical Development of Cancer Therapies 59
Helen X Chen
3.1 Introduction 59
3.2 A Few Definitions and General Concepts 60
3.3 Role of Biomarkers in the Different Stages of Drug Development 63
3.3.1 Use of PD Markers in Phase I and Early-Stage Proof of Principle Studies 64
3.3.1.1 Role of PD markers in verifying target engagement 64
3.3.1.2 Role of PD markers in decisions on the recommended phase II dose (RP2D): value and limitations 65
3.3.1.3 Use of distal PD markers to measure the biological and molecular consequences of target inhibition 67
3.3.2 Incorporation and Exploration of Patient Selection Markers in Early Clinical Trials 68
3.3.2.1 Trial design for patient selection markers 70
3.3.2.2 Scientific and technical challenges of predictive markers 71
3.4 Conclusions and Future Directions 73

4. HER-2 as a Prognostic and Predictive Biomarker in Cancer **77**
Suparna B. Wedam and Stanley Lipkowitz
4.1 Introduction 77
4.2 Biology of HER-2 78
4.3 HER-2 Amplification and Overexpression: Methods of HER-2 Measurement 81
4.4 HER-2 Amplification as a Prognostic Biomarker in Breast Cancer 85
4.5 HER-2 Amplification as a Predictive Biomarker for Response to HER-2 Targeted Agents in Breast Cancer 86
4.5.1 Trastuzumab 86
4.5.2 Lapatinib 91
4.5.3 Pertuzumab 93
4.6 HER-2 Amplification as a Predictive Biomarker for Response to Chemotherapy in Breast Cancer 93
4.7 HER-2 Amplification as a Predictive Biomarker for Response to Hormonal Therapy in Breast Cancer 96
4.8 Serum HER-2 Extracellular Domain (ECD) as a Biomarker in Breast Cancer 98
4.9 HER-2 Amplification as a Prognostic Biomarker and a Predictive Biomarker for Response to HER-2 Targeted Agents in Other Cancers 99
4.9.1 Gastric Cancer 99
4.9.2 Ovarian Cancer 100
4.9.3 Non-Small Cell Lung Cancer (NSCLC) 101
4.9.4 Transitional Cell Carcinoma (TCC) of the Urothelium 101
4.9.5 Colorectal Cancer 102
4.9.6 Other Tumors 102
4.10 Conclusions 102

5. Hormone Receptors and Endocrine Therapy in Breast Cancer **121**
Sherry X. Yang
5.1 Introduction 122
5.2 Biology of Hormone Receptors 122

5.3 ER/PgR as Prognostic and Therapeutic Biomarkers 123
5.3.1 ER and PgR as Prognostic Factors in Breast Cancer 124
5.3.2 ER and PgR as Therapeutic Biomarkers in Breast Cancer 125
5.4 ER/PgR Targeted Therapy for Breast Cancer 127
5.4.1 Adjuvant Endocrine Therapy 133
5.4.1.1 Premenopausal patients 133
5.4.1.2 Postmenopausal patients 134
5.4.2 Endocrine Therapy for Recurrent and Metastatic Disease 137
5.4.3 Neoadjuvant Endocrine Therapy 139
5.5 Endocrine Therapy Resistance 139
5.6 Diagnostic Tests for ER and PgR 141
5.6.1 Methods for Evaluation of ER/PgR Expression 141
5.6.2 Immunohistochemical Testing for ER and PgR 142
5.7 Conclusions 143

6. Predictive Biomarkers for Epidermal Growth Factor Receptor Agents in Non-Small Cell Lung Cancer 155
John Hilton, Penelope A. Bradbury, and Janet Dancey
6.1 Introduction 155
6.2 The Epidermal Growth Factor Receptor Family 156
6.3 Signal Transduction Pathways Controlled by the Activation of EGFR 157
6.4 EGFR Inhibitors for the Management of NSCLC 158
6.5 Activating EGFR Receptor Mutations 163
6.6 Biomarkers for Acquired Resistance to EGFR TKIs 167
6.7 EGFR Gene Amplification and Increased Protein Levels 167
6.8 K-Ras Mutations and Anti-EGFR Therapy 170
6.9 EGFR Ligands 171
6.10 Polymorphism Studies and Anti-EGFR Therapy 172
6.11 Circulating Tumor Cells in NSCLC Biomarker Research 173
6.12 Conclusions 174

7. Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer **183**

Jose G. Monzon and Janet Dancey

7.1 Introduction 183

7.2 The Epidermal Growth Factor Receptor (EGFR) Pathway and Colorectal Cancer 184

7.2.1 RAS/RAF/MAPK Pathway 186

7.2.2 PI3K/AKT Pathway 187

7.3 EGFR Inhibitors Used in Metastatic Colorectal Cancer (mCRC) 187

7.4 Determinants of Sensitivity and Resistance to EGFR Targeting moAbs 193

7.4.1 Clinical Features 194

7.4.1.1 EGFR inhibitor induced-skin rash 194

7.4.2 Potential predictive Genetic Alterations of the EGFR pathway in patients with mCRC 195

7.4.2.1 KRAS mutations 195

7.4.2.2 KRAS mutation detection 195

7.4.2.3 Specimen selection for KRAS mutation testing 198

7.4.2.4 Prognostic significance of KRAS mutation status 199

7.4.2.5 Predictive significance of KRAS mutation status 199

7.4.2.6 BRAF mutations in patients with mCRC 204

7.4.2.7 BRAF mutation detection in patients with mCRC 205

7.4.2.8 Specimen selection for BRAF mutation testing 205

7.4.2.9 Prognostic and predictive role of BRAF mutations 205

7.4.2.10 KRAS Let-7 single nucleotide polymorphism 206

7.4.3 Genetic Mutations Affecting the EGFR Gene 207

7.4.3.1 Somatic EGFR gene mutations 207

7.4.3.2 EGFR gene copy number 208

7.4.3.3 Measuring EGFR gene copy number 208
7.4.3.4 Specimen selection for EGFR gene copy number 209
7.4.3.5 Prognostic value of EGFR gene copy number 209
7.4.3.6 Predictive role of EGFR gene copy number 211
7.4.3.7 PIK3CA mutations 212
7.4.3.8 Measuring PIK3CA mutations 212
7.4.3.9 Specimen selection for PIK3CA mutation testing 212
7.4.3.10 Predictive role of PIK3CA mutation testing 213
7.4.4 Potential Predictive Alterations in Gene Expression of the EGFR Pathway 213
7.4.4.1 EGFR protein expression 213
7.4.4.2 EGFR ligands: amphiregulin and epiregulin 214
7.4.4.3 PTEN loss of expression 215
7.4.4.4 Measuring PTEN expression 215
7.4.4.5 Predictive role of loss of PTEN expression 216
7.5 Future Directions 217

8. Targeting BCR-ABL for Molecular Therapy of Chronic Myelogenous Leukemia 233
Shamudheen Rafiyath, Guoqing Wei, and Delong Liu
8.1 Pathogenesis 234
8.2 Structure of BCR-ABL 235
8.3 Mechanism of CML 236
8.4 Essential Features of BCR-ABL 237
8.5 Targeted Therapies of Chronic Myeloid Leukemia 238
8.5.1 First-Generation Tyrosine Kinase Inhibitors 238
8.5.1.1 Imatinib mesylate 238
8.5.1.2 Monitoring 240

此为试读,需要完整PDF请访问: www.ertongbook.com

8.5.1.3 Toxicity 240
8.5.1.4 Imatinib resistance 240
8.5.1.5 Mutation analysis 243
8.5.2 Second-Generation Tyrosine Kinase Inhibitors 243
8.5.2.1 Dasatinib 243
8.5.2.2 Nilotinib 246
8.5.3 Management of Resistance to First-Line TKIs 248
8.5.3.1 Bosutinib 251
8.5.3.2 Bafetinib (INNO-406) 252
8.6 Future Horizons in the Treatment of CML 253
8.6.1 T315I Kinase Inhibitors 253
8.6.2 Aurora Kinase Inhibitor 253
8.6.3 Omacetaxine Mepesuccinate 254
8.7 Conclusions and Future Directions 255

9. Gastrointestinal Stromal Tumors: From Molecular Pathogenesis to Therapy 267
Joaquina Baranda, Rashna Madan, and Andrew K. Godwin
9.1 Introduction 267
9.2 Molecular Pathogenesis of GIST 269
9.2.1 Mutations in RTKS: KIT 269
9.2.2 Mutations in RTKs: PDGFRA 272
9.2.3 BRAF Mutation 272
9.3 Hereditary, Syndromic and Variant GISTs 273
9.3.1 Hereditary/Familial GISTs 273
9.3.2 Neurofibromatosis I (NF1)-Associated GISTs 274
9.3.3 Carney's Triad-associated GISTs 274
9.3.4 Carney–Stratakis Syndrome (Carney's Dyad) 274
9.3.5 Pediatric GISTs 274
9.3.6 Risk Assessment 277
9.4 Treatment of GIST 278
9.4.1 Imatinib Mesylate 278
9.4.1.1 Efficacy of imatinib in patients with advanced GIST 279
9.4.1.2 Dose and efficacy 279

9.4.1.3 Duration of therapy 280
9.4.1.4 Management of toxicities 281
9.4.2 Sunitinib 282
9.4.2.1 Management of sunitinib toxicities 284
9.4.3 Sorafenib and Other Tyrosine Kinase Inhibitors 285
9.4.3.1 Assessment of response to therapy 286
9.4.3.2 Adjuvant therapy 287
9.4.4 Biomarkers That Predict Benefit, Response, and Resistance to Therapy 287
9.4.4.1 Response predictors in GIST 287
9.4.4.2 Imatinib plasma levels 290
9.4.4.3 Drug interactions 291
9.4.4.4 Imatinib resistance and intolerance 291
9.4.4.5 Benefit of imatinib as a function of risk stratification 292
9.4.4.6 Molecular biomarkers of therapeutic response 293
9.5 Summary 295

10. PML/RARα Fusion Gene and Response to Retinoic Acid and Arsenic Trioxide Treatment 313
Alicja M. Gruszka and Myriam Alcalay
10.1 Introduction 314
10.1.1 Description of Acute Promyelocytic Leukaemia 314
10.1.2 Modern Therapeutic Approaches 315
10.1.3 Treatment Complications and Prognosis 316
10.2 Molecular Pathogenesis 316
10.2.1 Translocation (15;17) and Cloning of the Fusion Gene 316
10.2.2 Partner Genes and Their Physiological Function 317
10.2.3 Mechanisms of Action of PML/RARα 318
10.2.3.1 Global transcriptional repression 319

10.2.3.2 Transcriptional activation 321
10.2.3.3 Deregulation of other haematopoietic transcription factors 322
10.2.3.4 Protein misfolding 323
10.2.4 Consequences of the Expression of PML/RARα 323
10.2.4.1 Differentiation block 323
10.2.4.2 Enhanced self-renewal 323
10.2.4.3 Apoptosis resistance 324
10.2.5 The Role of Cooperating Mutations 325
10.3 Mechanisms of Action of ATRA and Arsenic Trioxide 326
10.3.1 Mechanisms of ATRA Action 326
10.3.2 Mechanisms of Arsenic Trioxide Action 327
10.3.3 Synergy Between ATRA and Arsenic Trioxide 329
10.4 Conclusions 330

11. Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluorouracil Toxicity 337

Eva Gross and André B. P. van Kuilenburg

11.1 Introduction 337
11.2 Variability of the *DPYD* Gene 338
11.3 Epigenetic and Non-Genetic Effects on *DPYD* Dysregulation 341
11.4 Functional Testing of the DPD Status 342
11.5 Conclusion 343

12. UGT1A1 Polymorphisms and Mutations Lead to Irinotecan-Induced Toxicity 353

K. M. Reece and W. D. Figg

12.1 Irinotecan 353
12.2 The UGT1A Gene Complex 356
12.3 Pharmacogenetics of UGT1A1 357
12.4 Ethnic Differences in UGT1A1 Variants 359
12.5 Crigler–Najjar Syndrome 360
12.6 Gilbert's Syndrome 363
12.7 Conclusion 363

13. The 21-Gene Recurrence Score and Benefit of Chemotherapy in Estrogen Receptor-Positive Breast Cancer **369**

Petra Rietschel and Joseph A. Sparano

13.1 Introduction 369
13.2 Genomics 370
13.3 Development and Validation of Multiparameter Assays 370
13.4 Development of the 21-Gene Recurrence Score 371
13.5 Recurrence Score and Prognosis 374
13.6 Recurrence Score and Prediction of Chemotherapy Benefit 378
13.7 Impact of RS on Clinical Decision Making 379
13.8 Gene Expression Profiles and Expert Panels 381
13.9 Prospective Clinical Trials Evaluating Multiparameter Assays 382
13.10 Conclusion 382

14. MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients **387**

Sonal J. Desai and Tianhong Li

14.1 Introduction 387
14.2 Discovery of MammaPrint 388
14.3 Retrospective Clinical Validation 389
14.4 Analytic Development for MammaPrint as a Diagnostic Test 397
14.5 Prospective Clinical Validation of MammaPrint 398
14.6 Biologic Implication of MammaPrint Results 400
14.6.1 Understanding of Tumor Biology 400
14.6.2 Revealing New Therapeutic Targets 401
14.6.3 Prediction for Response or Resistance to Chemotherapy 403
14.6.4 Elucidation of Resistant Mechanisms to Chemotherapy 405
14.7 Potential Advantages of MammaPrint as a Prognostic Test 406
14.8 Challenges in Clinical Application of MammaPrint 407
14.9 Summary and Perspectives 408

15. *BRCA* Mutation and PARP Inhibitors **417**

Marcie K. Weil, Shivaani Kummar, James H. Doroshow, and Alice Chen

15.1 Introduction 417
15.2 *BRCA* 418
15.3 Poly (ADP-Ribose) Polymerase (PARP) 422
15.4 PARP Inhibitors as Single Agents to Induce Synthetic Lethality in *BRCA* Tumor Cells 425
15.5 PARP Inhibitors in Combination with Cytotoxic Therapy 426
15.6 PARP Inhibitors in Combination with Ionizing Radiation (XRT) 428
15.7 Clinical Development of PARP Inhibitors 428
15.7.1 Olaparib (AZD 2281, KU-0059436) 428
15.7.1.1 *BRCA*-mutation ovarian cancer and olaparib 429
15.7.1.2 *BRCA*-mutation associated breast cancer and olaprib 431
15.7.2 Veliparib (ABT888) 431
15.7.2.1 *BRCA* breast and ovarian cancers and TNBC with veliparib 432
15.7.3 Rucaparib (AG014699, PF01367338) 432
15.7.4 Iniparib (BSI 201, NSC-746045; IND-71677) 434
15.7.5 Niraparib (MK 4827) 435
15.8 Acquired Resistance to PARP Inhibitors 435
15.9 Future Directions 437

16. *EML4-ALK* Fusion Gene and Therapy with ALK-Targeted Agents in Non-Small Cell Lung Cancer **449**

Vimal Patel and Biren Saraiya

16.1 Introduction 449
16.2 The Identification of *EML4-ALK* in NSCLC 450
16.2.1 The Structure and Function of EML4 451
16.2.2 The Structure and Function of ALK 452
16.2.3 The ALK Gene Rearrangements in Cancer 453
16.2.4 The Structure of *EML4-ALK* and Other Non-EML4 Translocation Partners 454

16.2.5 The Transforming Activity of *EML4-ALK* 455
16.3 Clinical and Pathologic Features of *EML4-ALK* 456
16.4 Methods of Detection 458
16.4.1 Reverse Transcriptase-PCR Based Detection 459
16.4.2 Immunohistochemistry Based Detection 459
16.4.3 Fluorescence *in situ* Hybridization Based Detection 460
16.4.4 Potential Concerns Independent of the Method of Detection 462
16.5 Outcomes with Current Standard NSCLC Therapies 463
16.5.1 Preclinical ALK Targeted Therapies in NSCLC 464
16.5.2 Clinical Studies with Crizotinib 465
16.5.3 Resistance to Crizotinib and Emergence of New ALK Inhibitors 465
16.6 Future Directions 466

17. BRAF-Targeted Therapy in Metastatic Melanoma 473
Noori Kim and April Deng
17.1 Introduction 473
17.2 BRAF and the MAPK Pathway 474
17.3 BRAF V600E Mutation in Melanoma 476
17.4 Sorafenib and PLX4032 478
17.5 Other RAF Inhibitors 481
17.6 BRAF Inhibition Resistance Mechanisms 482
17.6.1 The Role of RAF Isoforms 482
17.6.2 The Role of IGF-1R and PI3K-AKT Pathway 483
17.6.3 Amplification of Cyclin-Dependent Kinase 484
17.6.4 The Role of Growth Factors 484
17.6.5 The Role of Cytokines 484
17.7 Final Thoughts 485

Index 491

此为试读，需要完整PDF请访问：www.ertongbook.com